Skip to main content

Table 1 Patients’ characteristics

From: Prucalopride reduces the number of reflux episodes and improves subjective symptoms in gastroesophageal reflux disease: a case series

  Patient 1 Patient 2 Patient 3 Patient 4
Age (years) 49 50 70 40
BMI (Du Bois) 35.9kg/m2 26.8kg/m2 21.9kg/m2 33.8kg/m2
GERD symptoms Heartburn, regurgitation Heartburn, regurgitation Regurgitation Heartburn, globus, bloating
GERD history - GERD symptoms >10 years - symptoms persistent to standard PPI - GERD symptoms >20 years - symptoms persistent to PPI - GERD symptoms >10 years - symptoms persistent to standard PPI - GERD symptoms for three months
- subjective impression of improved symptom control to treatment with ranitidine - GERD symptoms persistent after successful H. pylori eradication and ongoing standard PPI treatment
- start prucalopride six months after eradication
Endoscopic findings Small axial herniation, no reflux lesions Small axial herniation, ERD LA C Small axial herniation, no reflux lesions No axial herniation, no reflux lesions, H. pylori gastritis
  1. BMI – body mass index, ERD – erosive reflux disease, GERD – gastroesophageal reflux disease, H.p. – Helicobacter pylori, LA – Los Angeles classification, PPI – proton pump inhibitor.